Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|November 13, 2026 (Updated: November 13, 2026)

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach

FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Today: questions about two of FDA’s signature transparency and speed initiatives, a bispecific built for less frequent dosing, and an obesity candidate designed for once- or twice-yearly dosing.

First, FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot. The program aimed to cut reviews of drug and biologic applications to one to two months, versus six months or more under other priority programs. According to Reuters, no new vouchers have been awarded since former Commissioner Marty Makary resigned in mid-May, and the review council is dormant. FDA also appears to have stopped publishing new complete response letters, with no new entries in its public database in roughly three months. HHS disputes that the pilot is shelved, and an FDA spokesperson said the agency will keep publishing redacted CRLs.

Next, Zai Lab presented first-in-human data for ZL-1503, a long-acting bispecific antibody that blocks IL-13, which drives inflammation, and the IL-31 receptor, which drives itch. In 48 healthy volunteers, the half-life was about 40 to 50 days, supporting Zai Lab’s goal of maintenance dosing every 12 weeks. No dose-limiting toxicities or serious adverse events were reported. Data in patients with moderate-to-severe atopic dermatitis are expected in the first half of 2027.

And finally, Wave Life Sciences reported 1-year phase 1 data for WVE-007, a GalNAc-conjugated siRNA that silences INHBE, a gene linked to fat metabolism. After a single dose, the 240-milligram cohort showed placebo-adjusted reductions in visceral fat, total fat, and waist circumference at one year, with lean mass preserved. Wave is aiming for once- or twice-yearly dosing and expects phase 2a data in 2027.

That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways

  • Regulatory uncertainty: The reported pause on fast-track vouchers and CRL publication comes while FDA has no permanent commissioner.
  • Dosing intervals: ZL-1503’s long half-life could allow patients with atopic dermatitis to be dosed only a few times a year.
  • Body composition: Wave is betting on fat loss that spares muscle, though the magnitude of the changes hasn’t been disclosed.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more